Stephen Davis Acadia Pharmaceuticals Inc (ACAD) insider trading activity

Stephen Davis is CEO of ACADIA PHARMACEUTICALS INC. Currently has a direct ownership of 186,555 shares of ACAD, which is worth approximately $3.04 Million. The most recent transaction as insider was on Jan 06, 2023, when has been sold 9,528 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 187K

0% 3M change

109.3% 12M change

Total Value Held $3.04 Million

STEPHEN DAVIS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2023	BUY Exercise of conversion of derivative security	-	9,528 Added 9.72%	88,537 Common Stock
Oct 15 2022	SELL Open market or private sale	$44,331 $15.81 p/Share	2,804 Reduced 3.43%	79,009 Common Stock
Oct 15 2022	BUY Exercise of conversion of derivative security	-	5,938 Added 6.77%	81,813 Common Stock
May 02 2022	SELL Open market or private sale	$99,681 $18.18 p/Share	5,483 Reduced 6.74%	75,875 Common Stock
Apr 29 2022	BUY Exercise of conversion of derivative security	-	15,625 Added 16.11%	81,358 Common Stock
Feb 23 2022	SELL Open market or private sale	$93,486 $23.8 p/Share	3,928 Reduced 5.64%	65,733 Common Stock
Feb 23 2022	BUY Exercise of conversion of derivative security	-	10,945 Added 13.58%	69,661 Common Stock
Jan 06 2022	SELL Open market or private sale	$85,700 $23.05 p/Share	3,718 Reduced 5.96%	58,716 Common Stock
Jan 06 2022	BUY Exercise of conversion of derivative security	-	9,527 Added 13.24%	62,434 Common Stock
Oct 18 2021	SELL Open market or private sale	$51,586 $17.41 p/Share	2,963 Reduced 5.3%	52,906 Common Stock
Oct 15 2021	BUY Exercise of conversion of derivative security	-	5,938 Added 9.61%	55,869 Common Stock
Apr 30 2021	SELL Open market or private sale	$159,590 $20.33 p/Share	7,850 Reduced 13.73%	49,312 Common Stock
Apr 29 2021	BUY Exercise of conversion of derivative security	-	15,625 Added 21.47%	57,162 Common Stock
Feb 04 2021	SELL Open market or private sale	$718,409 $50.61 p/Share	14,195 Reduced 32.94%	28,900 Common Stock
Feb 04 2021	BUY Grant, award, or other acquisition	-	31,250 Added 42.05%	43,059 Common Stock
Jan 06 2021	SELL Open market or private sale	$185,837 $53.34 p/Share	3,484 Reduced 12.46%	24,482 Common Stock
Jan 06 2021	BUY Exercise of conversion of derivative security	-	9,527 Added 25.41%	27,966 Common Stock
Oct 16 2020	SELL Open market or private sale	$125,978 $42.56 p/Share	2,960 Reduced 16.68%	14,786 Common Stock
Oct 15 2020	BUY Exercise of conversion of derivative security	-	5,937 Added 25.07%	17,746 Common Stock

Also insider at

HRTX

HERON THERAPEUTICS, INC. Healthcare

Director

BLCM

BELLICUM PHARMACEUTICALS, INC Healthcare

Director

Stephen Davis

CEO

Houston, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Value

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

Operation

Value

Type

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD

Account